{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.5","upperLimit":"18.7","value":"15.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of first dose until the date of death from any cause, estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg AIBW administered IV on Day 1 of every 3-week cycle (Q3W).","id":"OG000","title":"Mirvetuximab Soravtansine"}],"paramType":"MEDIAN","populationDescription":"INV Efficacy Evaluable population was defined as all participants who received at least 1 dose of study drug and who had measurable disease at baseline by investigator assessment per RECIST 1.1.","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months","title":"Overall Survival Assessed by the Investigator Using RECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}